SHERPA

Worldwise Names Senior Pet Industry Executive Jeff Sutherland as Chief Operating Officer

Retrieved on: 
Wednesday, May 25, 2022
SHERPA, Company, University of Arizona, Food, Energy, On-board, Discovery Air, Foodservice, Association, Marketing, Northern Arizona University, Industry, Central Gardens Nature Reserve, PETS, Child, Safety, Travel, Corporate services, Dog, AMCP, Growth, Financial services, Alvarez and Marsal, Amazon, Consumer, Health care

NOVATO, Calif., May 25, 2022 /PRNewswire/ -- Worldwise, Inc. ("Worldwise" or the "Company"), a leading pet supplies platform and a portfolio company of A&M Capital Partners ("AMCP"), a middle-market private equity investment fund that is part of the A&M Capital platform, together with A&M Capital Opportunities Fund, an affiliated fund, announced today that Jeff Sutherland has joined the Company as its Chief Operating Officer ("COO"), effective immediately. A proven operator with over 30 years of diverse pet industry experience, Mr. Sutherland will work closely with the Company's CEO Kevin Fick, its management team, and its private equity sponsor to further optimize enterprise-wide operations and support the Company's continued growth.

Key Points: 
  • "Jeff is an accomplished executive and esteemed leader within our industry, and bringing him onboard is a major development for Worldwise," said Mr. Fick.
  • On behalf of the entire Worldwise family, I want to welcome Jeff to the team."
  • Mr. Sutherland joins Worldwise from Redbarn Products ("Redbarn"), a family-owned manufacturer of premium pet food, treats, and chews, where he served as President since August 2017.
  • Worldwise, Inc. is committed to creating the most innovative, accessible, affordable, and environmentally-responsible product solutions for pets and pet parents everywhere.

Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022

Retrieved on: 
Wednesday, March 23, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Method, Nucleic acid thermodynamics, Recurrence, Neoplasm, LinkedIn, Epitope, Plasma, Population, MRD, DNA, PPM, Leadership, College, Form, KIT, Colorectal cancer, Clinical Laboratory Improvement Amendments, Form S-3, AACR, Genomics, GIST, American Association, College of American Pathologists, Cancer, Allele, SVP, 2021 Essex County Council election, Gastrointestinal stromal tumor, Immune system, MHC, Association, American Association for Cancer Research, Twitter, U.S. Securities and Exchange Commission, Liquid biopsy, SHERPA, Nasdaq, Gene, PDGFRA, Efficiency, PSNL, TKI, Patient, BCR, Prognosis, Medical imaging, Chief Justice of Hungary

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced it is presenting new data in scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2022 , which will be held in-person and online, April 8-13, 2022.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced it is presenting new data in scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2022 , which will be held in-person and online, April 8-13, 2022.
  • However, studies typically utilize assays limited to a small set of genes that may miss biologically important and clinically actionable mutations.
  • The NeXT Liquid Biopsy platform enables the identification of somatic variants in liquid biopsy samples, following interventions such as surgery and treatment therapies.
  • To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency.

Personalis Announces Updates to NeXT Platform™ Incorporating Additional Key Profiling Capabilities for Advancing Oncology Biomarkers

Retrieved on: 
Tuesday, November 2, 2021
Research, General Health, Pharmaceutical, Oncology, Genetics, Public Relations, Investor Relations, Clinical Trials, Science, Biotechnology, Communications, Other Science, Health, MD, Efficiency, SVP, College of American Pathologists, LinkedIn, Cancer, Veterans' affairs, College, Clinical Laboratory Improvement Amendments, Genomics, PSNL, Neoplasm, Twitter, Machine learning, U.S. Securities and Exchange Commission, Leadership, SHERPA, Biomarker, COVID-19, Growth, Nasdaq, Immune system, Veteran, Medical imaging

These new NeXT Platform features open up opportunities to further enhance composite biomarkers like NEOPS.

Key Points: 
  • These new NeXT Platform features open up opportunities to further enhance composite biomarkers like NEOPS.
  • These advanced machine learning and algorithmic tools paired with the unique assay design of the NeXT Platform, further Personalis goal of providing the most comprehensive genomic tumor profiling platform available.
  • The NeXT Platform consolidates multiple biomarker assays into one, enabling a seamless path from translational research to companion diagnostics development.
  • Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics.

Personalis Publishes New Data Demonstrating Performance and Utility of SHERPA for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development

Retrieved on: 
Tuesday, October 26, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Method, MD, Peptide, Immunotherapy, Efficiency, SVP, College of American Pathologists, Allele, Cancer, Veterans' affairs, College, Clinical Laboratory Improvement Amendments, Genomics, Molecular & Cellular Proteomics, PSNL, Twitter, U.S. Securities and Exchange Commission, Leadership, HLA, SHERPA, Biomarker, COVID-19, Growth, Systematic, MHC, Nasdaq, Proteomics, Immune system, Veteran, CMO, Medical imaging

To improve performance and generalizability, SHERPA was trained with immunopeptidomics data from newly engineered cell lines mono-allelic for HLA combined with other publicly available datasets.

Key Points: 
  • To improve performance and generalizability, SHERPA was trained with immunopeptidomics data from newly engineered cell lines mono-allelic for HLA combined with other publicly available datasets.
  • In addition, SHERPA was designed to more comprehensively capture epitope binding and presentation features to further enhance the predictive power of the algorithm.
  • Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics.
  • To enable cancer and population sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency.

HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline With Two Lead Immuno-Oncology Programs and Validate Its DIS™ Approach in the Clinic

Retrieved on: 
Monday, June 14, 2021
FDA, Other Professional Services, Other Health, Finance, Pharmaceutical, Banking, Oncology, General Health, Professional services, Infectious diseases, Clinical trials, Biotechnology, Science, Other Science, Research, Health, Finance, Money, SHERPA, Venture capital, Financial economics, Mirae Asset Financial Group, B Capital Group, Sherpa Healthcare Partners, Maison Capital, Trinity Innovation Fund, HiFiBiO Therapeutics, MIRAE ASSET FINANCIAL GROUP, B CAPITAL GROUP, SHERPA HEALTHCARE PARTNERS, MAISON CAPITAL, TRINITY INNOVATION FUND, HIFIBIO THERAPEUTICS

HiFiBiO Therapeutics , a multinational biotechnology company with unique expertise in immune modulation and drug intelligent science, today announced the completion of an oversubscribed $75M Series D financing round.

Key Points: 
  • HiFiBiO Therapeutics , a multinational biotechnology company with unique expertise in immune modulation and drug intelligent science, today announced the completion of an oversubscribed $75M Series D financing round.
  • Further, B Capital Group, Sherpa, Maison Capital, Trinity Innovation Fund, Grand Mount, and HKSTP Venture Fund also participated in this round.
  • Additionally, the company will continue to advance multiple pipeline programs through discovery and clinical development.
  • In addition, HiFiBiO Therapeutics aspires to address unmet medical needs around the world through open-innovation partnerships with industry and academia.

Spaceflight Inc.’s Next-Gen Sherpa OTV Program Showcases Innovative Modular Design of its Flight-Proven Subsystems

Retrieved on: 
Monday, June 7, 2021
Technology, Aerospace, Manufacturing, Satellite, Spaceflight, Outer space, Spacecraft, Spacecraft propulsion, SHERPA, SpaceX Mars program, OTV, Secondary payload, SpaceX, Spaceflight, Inc.

View the full release here: https://www.businesswire.com/news/home/20210607005017/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210607005017/en/
    The team preps Spaceflight's two OTVs for flight on SpaceX's Transporter-2 mission (SXRS-5).
  • (Photo: Business Wire)
    The modular design enables Spaceflight to quickly customize the OTVs with different propulsion systems and subsystems to deliver highly varied capabilities to meet customers unique needs for orbital deployment.
  • In its simplest form, Spaceflights OTV is a free-flying rideshare deployer; in its most advanced state, its an interplanetary transport vehicle.
  • For a first-hand, in-depth look at the technology, subsystems and capabilities behind the companys Sherpa program, register to attend Spaceflights Sherpa OTV Program: A Closer Look webinar tomorrow, June 8, at 11 a.m. PT here .

Sherpa Digital Media Delivers Key Metrics on Virtual Events and Video Streaming in 2020

Retrieved on: 
Wednesday, May 26, 2021
Concurrent computing, Articles, Distributed computing, Internet broadcasting, SHERPA, SHERPA, Online video platform, Virtual event, Hybrid event, Streaming media

Sherpa expects to see many more companies incorporating streaming technology and hosting hybrid events as this becomes the de facto event experience.

Key Points: 
  • Sherpa expects to see many more companies incorporating streaming technology and hosting hybrid events as this becomes the de facto event experience.
  • "At GovExec, we ran more than 200 virtual events last year and embedded video on a variety of pages," says Government Executive Management Group's Director of Events George Jackson.
  • Sherpa Digital Media enables high-quality virtual experiences for sales and marketing at scale through its live and on-demand video platform.
  • With decades of experience in video and virtual events, Sherpa streamlines the creation and delivery processes with end-to-end production and technology solutions.

Airheart Explorer Launches to Help Consumers Navigate Complicated Travel Restrictions & Policies

Retrieved on: 
Tuesday, May 18, 2021
Airheart, Renken, SHERPA, Video gaming, Video games

b'AUSTIN, Texas, May 18, 2021 /PRNewswire/ --Today Airheart unveiled their free tool, Explorer , to help people travel again, safely.

Key Points: 
  • b'AUSTIN, Texas, May 18, 2021 /PRNewswire/ --Today Airheart unveiled their free tool, Explorer , to help people travel again, safely.
  • Travelers can now discover which destinations are accessible and what\'s required for their trip, all through one user-friendly platform.\nNow more than ever, navigating restrictions and policies for travel is overwhelming.
  • Airheart eliminates the guesswork, so people can travel with confidence.\nAirheart\'s data is aggregated from official sources by our data partners, including Sherpa .
  • Our long-term vision is to create a place for organizing and managing the full lifecycle of a trip, starting with discovery using Airheart Explorer," said co-founder and CEO, Lindsey Renken.

Spaceflight Inc. Readies 36 Customer Spacecraft and Two OTVs for Launch on SpaceX’s Transporter-2 Mission

Retrieved on: 
Tuesday, May 11, 2021
Technology, Aerospace, Manufacturing, Satellite, Spaceflight, SHERPA, Spacecraft propulsion, Outer space, Private spaceflight, SpaceX, CubeSat, Spaceflight Industries

b"Spaceflight Inc. , the leading global launch services provider, announced today it will be launching 36 customer payloads to Sun Synchronous orbit aboard the SpaceX Transporter-2 mission, scheduled to launch no earlier than June 2021.

Key Points: 
  • b"Spaceflight Inc. , the leading global launch services provider, announced today it will be launching 36 customer payloads to Sun Synchronous orbit aboard the SpaceX Transporter-2 mission, scheduled to launch no earlier than June 2021.
  • The company purchased three ports on the mission, dubbed \xe2\x80\x98SXRS-5\xe2\x80\x99 by Spaceflight, and is managing the launch integration and mission management services for 36 payloads, including six microsatellites, 29 cubesats and one hosted payload.
  • The mission also represents the first time the company will fly two different orbital transportation vehicles (OTVs) and the launch of the industry\xe2\x80\x99s first-ever electric propulsion vehicle, Sherpa-LTE1.\nThis press release features multimedia.
  • \xe2\x80\x9cWe knew we needed to utilize two Sherpa OTVs to support the customer demand and saw a unique opportunity to fly Sherpa-LTE for the first time.

Travel Tech Company Sherpa˚ Launches Interactive Travel Reopening Map; Announces American Airlines as First Partner

Retrieved on: 
Thursday, April 8, 2021
Airline, SHERPA, Tourism, SHERPA, Human activities

TORONTO, April 8, 2021 /PRNewswire/ --Leading travel tech company sherpa powers the return to travel by expanding its product offering with their Travel Reopening Map .

Key Points: 
  • TORONTO, April 8, 2021 /PRNewswire/ --Leading travel tech company sherpa powers the return to travel by expanding its product offering with their Travel Reopening Map .
  • American Airlines was the first partner to launch the map, making it accessible to millions of AA's customers.
  • "International travel is an important part of our global economy and human experience; yet, planning travel in a global pandemic is a challenge," said sherpa CEO, Max Tremaine.
  • Founded in 2015 by Max Tremaine and Ivan Sharko, sherpa is the leading provider of travel identification requirements for the travel industry.